Method

Abstract

The present invention relates to peptides derivable from a component of myelin, namely myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) or myelin proteolipid protein (PLP), for use in the treatment or prevention of impaired cognition, particularly in subjects with multiple sclerosis (MS), dementia and/or demyelination in a subject. The peptides may be used in methods of treating subjects with impaired cognition, or preventing impaired cognition, particularly in subjects with MS, treating subjects with dementia, or preventing dementia, and/or treating demyelination in a subject, or preventing demyelination in a subject.

1 . A method for treating or preventing cognitive impairment in a subject comprising administering to the subject a peptide derived or derivable from a component of myelin selected from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and myelin proteolipid protein (PLP). 
     
     
         2 . The method according to  claim 1  wherein said subject has a demyelinating disease. 
     
     
         3 . The method according to  claim 2  wherein said subject has multiple sclerosis, Alzheimer's disease or Parkinson's disease. 
     
     
         4 . The method according to any one of  claims 1  to  3  wherein said peptide is selected from SEQ ID Nos. 1, 2, 3 and 4. 
     
     
         5 . The method according to any one of  claims 1  to  4  wherein peptides of SEQ ID Nos. 1, 2, 3 and 4 are administered to said subject. 
     
     
         6 . The method according to any one of  claims 1  to  3  wherein said peptide is selected from SEQ ID Nos. 7, 8, 9 and 10. 
     
     
         7 . The method according to any one of  claims 1  to  3  and  6  wherein peptides of SEQ ID Nos. 7, 8, 9 and 10 are administered to said subject. 
     
     
         8 . The method according to any one of  claims 1  to  3  wherein said peptide is selected from SEQ ID Nos. 12, 16, 18, 23, 24, 25, 26, 27, 28, 29, 30 and 31. 
     
     
         9 . The method according to any one of  claims 1  to  8  wherein said treatment leads to an improved PASAT score for said subject. 
     
     
         10 . A peptide as defined in any one of  claims 4  to  8  for use in treating or preventing impaired cognition in a subject. 
     
     
         11 . Use of a peptide as defined in any one of  claims 4  to  8  in the manufacture of a medicament for treating or preventing impaired cognition in a subject. 
     
     
         12 . The peptide for use according to  claim 10  or use of a peptide according to  claim 11  wherein said subject has a demyelinating disease. 
     
     
         13 . The peptide for use or use of a peptide according to  claim 12  wherein said subject has multiple sclerosis, Alzheimer's disease or Parkinson's disease. 
     
     
         14 . The peptide for use or use of a peptide according to any one of  claims 11  to  13  wherein said treatment leads to an improved PASAT score for said subject. 
     
     
         15 . A kit for use in treating or preventing impaired cognition in a subject, wherein said kit comprises a peptide as defined in any one of  claims 4  to  8 . 
     
     
         16 . A method for treating or preventing dementia in a subject comprising administering to the subject a peptide derived or derivable from a component of myelin selected from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and myelin proteolipid protein (PLP). 
     
     
         17 . The method according to  claim 16  wherein said subject has Alzheimer's disease. 
     
     
         18 . The method according to  claim 16  wherein said subject has Parkinson's disease. 
     
     
         19 . The method according to any one of  claims 16  to  18  wherein said peptide is selected from SEQ ID Nos. 1, 2, 3 and 4. 
     
     
         20 . The method according to any one of  claims 16  to  19  wherein peptides of SEQ ID Nos. 1, 2, 3 and 4 are administered to said subject. 
     
     
         21 . The method according to any one of  claims 16  to  18  wherein said peptide is selected from SEQ ID Nos. 7, 8, 9 and 10. 
     
     
         22 . The method according to any one of  claims 16  to  18  and  21  wherein peptides of SEQ ID Nos. 7, 8, 9 and 10 are administered to said subject. 
     
     
         23 . The method according to any one of  claims 16  to  18  wherein said peptide is selected from SEQ ID Nos. 12, 16, 18, 23, 24, 25, 26, 27, 28, 29, 30 and 31. 
     
     
         24 . A peptide as defined in any one of  claims 19  to  23  for use in treating or preventing dementia in a subject. 
     
     
         25 . Use of a peptide as defined in any one of  claims 19  to  23  in the manufacture of a medicament for treating or preventing dementia in a subject. 
     
     
         26 . The peptide for use according to  claim 24  or use of a peptide according to  claim 25  wherein said subject has Alzheimer's disease. 
     
     
         27 . The peptide for use according to  claim 24  or use of a peptide according to  claim 25  wherein said subject has Parkinson's disease. 
     
     
         28 . A kit for use in treating or preventing dementia in a subject, wherein said kit comprises a peptide as defined in any one of  claims 19  to  23 . 
     
     
         29 . A method for treating or preventing demyelination in a subject comprising administering to the subject a peptide derived or derivable from a component of myelin selected from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and myelin proteolipid protein (PLP). 
     
     
         30 . The method according to  claim 29  wherein said subject has a neurodegenerative disease. 
     
     
         31 . The method according to  claim 29  wherein said subject has multiple sclerosis, Alzheimer's disease, or Parkinson's disease. 
     
     
         32 . The method according to any one of  claims 29  to  31  wherein said peptide is selected from SEQ ID Nos. 1, 2, 3 and 4. 
     
     
         33 . The method according to any one of  claims 29  to  32  wherein peptides of SEQ ID Nos. 1, 2, 3 and 4 are administered to said subject. 
     
     
         34 . The method according to any one of  claims 29  to  31  wherein said peptide is selected from SEQ ID Nos. 7, 8, 9 and 10. 
     
     
         35 . The method according to any one of  claims 29  to  31  and  34  wherein peptides of SEQ ID Nos. 7, 8, 9 and 10 are administered to said subject. 
     
     
         36 . The method according to any one of  claims 29  to  31  wherein said peptide is selected from SEQ ID Nos. 12, 16, 18, 23, 24, 25, 26, 27, 28, 29, 30 and 31. 
     
     
         37 . A peptide as defined in any one of  claims 32  to  36  for use in treating or preventing demyelination in a subject. 
     
     
         38 . Use of a peptide as defined in any one of  claims 32  to  36  in the manufacture of a medicament for treating or preventing demyelination in a subject. 
     
     
         39 . The peptide for use according to  claim 37  or use of a peptide according to  claim 38  wherein said subject has a neurodegenerative disease. 
     
     
         40 . The peptide for use according to  claim 37  or use of a peptide according to  claim 38  wherein said subject has multiple sclerosis, Alzheimer's disease, or Parkinson's disease. 
     
     
         41 . A kit for use in treating or preventing demyelination in a subject, wherein said kit comprises a peptide as defined in any one of  claims 32  to  36 .